Yiru Zhang1,2,3, Vibeke Sørensen Catts1,2,3, Cynthia Shannon Weickert1,2,3. 1. 1 Schizophrenia Research Institute, Sydney, NSW, Australia. 2. 2 Schizophrenia Research Laboratory, Neuroscience Research Australia, Randwick, NSW, Australia. 3. 3 School of Psychiatry, University of New South Wales, Sydney, NSW, Australia.
Abstract
OBJECTIVE: The glutathione (GSH) pathway is the main antioxidant system to protect against oxidative stress in the human brain. In this study, we tested whether molecular components of the GSH antioxidant system are changed in dorsolateral prefrontal cortex tissue from people with schizophrenia compared to controls. METHOD: The levels of total glutathione and reduced GSH were determined by fluorometric assay via quantifying thiols in extracts from frontal cortex of 68 people. Immunoblotting was used to measure levels of enzymes responsible for maintaining GSH, the glutamyl-cysteine ligase (GCL) catalytic subunit (GCLC) and the GSH peroxidase (GPx)-like protein ( n = 74). Quantitative reverse transcription polymerase chain reaction (RT-PCR) was used to measure GCLC messenger RNA (mRNA) expression. RESULTS: Both total glutathione ( t(66) = 2.467, p = 0.016) and reduced GSH ( t(66) = 3.001, p = 0.004) levels were significantly less in people with schizophrenia than in controls. However, there were no significant differences in either GCLC-like protein ( t(72) = -1.077, p = 0.285) or GCLC mRNA expression ( t(71) = -0.376, p = 0.708) between people with schizophrenia and control subjects. There was also no significant difference of GPx-like protein levels between schizophrenia and controls ( t(72) = -0.060, p = 0.952). Moreover, no significant correlations of putative confounding factors with GSH changes were detected. DISCUSSION: These results suggest that people with schizophrenia have impaired GSH antioxidant capacity, alongside normal levels of key regulatory proteins.
OBJECTIVE: The glutathione (GSH) pathway is the main antioxidant system to protect against oxidative stress in the human brain. In this study, we tested whether molecular components of the GSH antioxidant system are changed in dorsolateral prefrontal cortex tissue from people with schizophrenia compared to controls. METHOD: The levels of total glutathione and reduced GSH were determined by fluorometric assay via quantifying thiols in extracts from frontal cortex of 68 people. Immunoblotting was used to measure levels of enzymes responsible for maintaining GSH, the glutamyl-cysteine ligase (GCL) catalytic subunit (GCLC) and the GSH peroxidase (GPx)-like protein ( n = 74). Quantitative reverse transcription polymerase chain reaction (RT-PCR) was used to measure GCLC messenger RNA (mRNA) expression. RESULTS: Both total glutathione ( t(66) = 2.467, p = 0.016) and reduced GSH ( t(66) = 3.001, p = 0.004) levels were significantly less in people with schizophrenia than in controls. However, there were no significant differences in either GCLC-like protein ( t(72) = -1.077, p = 0.285) or GCLC mRNA expression ( t(71) = -0.376, p = 0.708) between people with schizophrenia and control subjects. There was also no significant difference of GPx-like protein levels between schizophrenia and controls ( t(72) = -0.060, p = 0.952). Moreover, no significant correlations of putative confounding factors with GSH changes were detected. DISCUSSION: These results suggest that people with schizophrenia have impaired GSH antioxidant capacity, alongside normal levels of key regulatory proteins.
Authors: Kuldeep Dhama; Shyma K Latheef; Maryam Dadar; Hari Abdul Samad; Ashok Munjal; Rekha Khandia; Kumaragurubaran Karthik; Ruchi Tiwari; Mohd Iqbal Yatoo; Prakash Bhatt; Sandip Chakraborty; Karam Pal Singh; Hafiz M N Iqbal; Wanpen Chaicumpa; Sunil Kumar Joshi Journal: Front Mol Biosci Date: 2019-10-18
Authors: Chad A Bousman; Sandra Luza; Serafino G Mancuso; Dali Kang; Carlos M Opazo; Md Shaki Mostaid; Vanessa Cropley; Patrick McGorry; Cynthia Shannon Weickert; Christos Pantelis; Ashley I Bush; Ian P Everall Journal: Sci Rep Date: 2019-02-19 Impact factor: 4.379
Authors: Kun Yang; Anouk Marsman; Subechhya Pradhan; Jennifer M Coughlin; Min Wang; Rebecca E Ward; Susanne Bonekamp; Emily B Ambinder; Cecilia P Higgs; Pearl K Kim; Jamie A Edwards; Mark Varvaris; Hongxing Wang; Sotirios Posporelis; Shuangchao Ma; Tsuyoshi Tsujimura; Richard A E Edden; Martin G Pomper; Thomas W Sedlak; Margot Fournier; David J Schretlen; Nicola G Cascella; Peter B Barker; Akira Sawa Journal: Mol Psychiatry Date: 2020-10-19 Impact factor: 15.992